olanzapine and melatonin

PreclinicalSmall molecule

SSeattle Institute for Biomedical and Clinical Research

olanzapine and melatonin is one of 57 small molecule programs targeting Schizoaffective Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Schizoaffective DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Schizoaffective Disorder

#DrugCompanyPhaseTrials

Risperdal

WWim Janssens

Approved

18 2

Zyprexa

MMODAG GmbH

Approved

10 3

Nicorette

Pfizer

Approved

1 4

Estrace

Meridia

1 6

Nuvigil

NNuvo Research GmbH

Approved

1 7

Haldol

DDePuy Orthopaedics

Approved

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 9

Versed

CConrado Roberto Hoffmann Filho

Approved

—10

Targretin

BBausch Health Americas, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizoaffective Disorder1 trial

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

Completed·SSeattle Institute for Biomedical and Clinical Research·N/A·NCT00512070·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for olanzapine and melatonin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — olanzapine and melatonin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for olanzapine and melatonin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Institute for Biomedical and Clinical Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeattle Institute for Biomedical and Clinical Research

olanzapine and melatonin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizoaffective Disorder1 trial

References

Drug Info

Quick Facts

Related News